Harbor Capital Advisors Inc. Raises Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Harbor Capital Advisors Inc. increased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 1.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 40,987 shares of the company’s stock after acquiring an additional 684 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Kymera Therapeutics were worth $1,649,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Values First Advisors Inc. acquired a new stake in shares of Kymera Therapeutics in the third quarter valued at approximately $61,000. Quarry LP acquired a new stake in Kymera Therapeutics during the 3rd quarter valued at $95,000. Mirae Asset Global Investments Co. Ltd. increased its position in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in shares of Kymera Therapeutics in the second quarter valued at $139,000. Finally, Quest Partners LLC boosted its stake in shares of Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after acquiring an additional 4,865 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Oppenheimer boosted their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Friday, September 27th. Truist Financial reissued a “buy” rating and set a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. BTIG Research started coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $60.00 target price for the company. Stephens began coverage on Kymera Therapeutics in a research note on Monday, November 18th. They set an “overweight” rating and a $65.00 price target on the stock. Finally, Guggenheim lifted their price objective on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $55.38.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the sale, the insider now owns 54,826 shares of the company’s stock, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.82% of the company’s stock.

Kymera Therapeutics Stock Down 5.8 %

Kymera Therapeutics stock opened at $38.17 on Monday. The firm has a fifty day moving average of $43.92 and a 200-day moving average of $44.13. Kymera Therapeutics, Inc. has a 52-week low of $26.34 and a 52-week high of $53.27. The firm has a market capitalization of $2.47 billion, a P/E ratio of -16.31 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The firm had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm’s quarterly revenue was down 20.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.90) EPS. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.